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recommendations on dose. Recent studies have suggested that
some critically ill patients fail to achieve sufficient plasma antibi-
otic concentrations to treat infection effectively.2
We determined whether critically-ill patients with respiratory
infection achieved pharmacokinetic/pharmacodynamic (PK/PD)
targets during antibiotic treatment and investigated factors associ-
ated with failure to meet these targets.
Methods This was a subgroup, interim analysis of an ongoing
study, ABDose. Participants were adults in intensive care receiving
piperacillin-tazobactam or co-amoxiclav for respiratory infection.
Demographics and measures of organ function were recorded.
Antibiotic concentrations were measured, at steady-state, in
plasma at 50% and 100% of the dosing interval. Efficacy of beta-
lactam antibiotics is dependent upon time above minimum inhibi-
tory concentration(MIC). We chose PK/PD targets of antibiotic
concentration >MIC and a more conservative >4 × MIC of
likely pathogen or microbiological isolate (when available). These
targets have been used previously.2 During 28-day follow up,
need for additional antibiotics was recorded.
Results 24 participants (median age 61, IQR [50–70] years),
received co-amoxiclav (n = 7), piperacillin-tazobactam (n = 15)
or both (n = 2). At 100% of the dosing interval, 12 achieved
plasma antibiotic concentrations >MIC and 8
achieved >4×MIC. Participants who did not achieve PK/PD tar-
gets were younger (48 [39–59] years vs 68 [61–80] years,
p = 0.002*) and had a higher eGFR (131 ± 58 mls/min/1.73m2
vs 64 ± 28 mls/min/1.73m2, p = 0.004*) than those who did.
Antibiotic concentrations were correlated with age and negatively
correlated with eGFR (Figure 1). All participants failing to
achieve antibiotic concentrations >4 × MIC at 100% of the dos-
ing interval required further courses of antibiotics during follow-
up compared to 50% of patients achieving this target
(p = 0.02*).
Conclusion In critically-ill patients with respiratory infection,
uniform dosing of beta-lactam antibiotics does not consistently
achieve PK/PD targets required for optimal efficacy. Younger
patients, with better renal function may be under-dosed. These
interim findings identify a need for further work to determine
whether personalised dynamic dosing regimens could improve
outcomes for patients with severe respiratory infection. Popula-
tion PK modelling and further covariate analysis is planned
within ABDose.
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Introduction The REVIVE RCT investigated the effectiveness of
an individually tailored (personalised) exercise programme for
patients discharged from hospital after critical illness.1 By
including qualitative methods, we aimed to explore their percep-
tions of engaging in the 6 week programme to facilitate a better
understanding of the intervention and trial outcomes.
Methods Patients allocated to the exercise group were invited to
participate in semi-structured interviews following their final out-
come assessment (6 months following randomisation). Interviews
were conducted by a trained member of the research team not
involved in the intervention. Interviews were audio recorded,
transcribed verbatim and content analysis used to explore themes
arising from the data.
Results Of 30 patients allocated to the exercise group 21 com-
pleted interviews. Seven core themes were identified (1) sequelae
of critical illness and critical care recovery; (2) satisfaction and
endorsement of the exercise programme; (3) beneficial impact of
the exercise programme on physical and psychological health; (4)
facilitators of beneficial impact; (5) barriers to beneficial impact;
(6) challenges to continuing exercise; (7) contrasting views on
outcome measures.
Patients provided insight into the physical and mental sequelae
they experienced following critical illness. There was a strong
sense of patients’ need for the exercise programme and its impor-
tance for their recovery following discharge home. The pro-
gramme was described as invaluable, and provided feelings of
motivation and hope. Key facilitators of beneficial impact
included supervision, tailoring of the exercises to personal needs,
and the manual. Barriers to the beneficial impact of the pro-
gramme included poor mental health, existing physical limita-
tions and lack of motivation. Patients’ views of the questionnaires
and performance based outcome measures in the REVIVE trial
varied. Many patients were unsure about what would be the best
way of measuring how the programme affected their health.
Conclusion The benefits of physical rehabilitation programmes,
needs to be counterbalanced against patients’ mental health status
post-ICU and any pre-admission limitations, if they are to be suc-
cessful. Including this qualitative component improved our
understanding of the mechanisms underpinning the impact of the
programme and how programmes should be evolved for future
trials.
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Introduction and objective The BALTI-Prevention Trial1 transla-
tional sub-study (recruitment completed in 2011) and VINDA-
LOO Trial2 (recruitment completed in 2015) both used
oesophagectomy as a model for investigation of the pharmacolog-
ical prevention of ARDS. The VINDALOO trial showed a lower
ARDS incidence independent of the agents evaluated. Our objec-
tive was to characterise this difference.
Methods Databases from both trials were available and additional
information was obtained retrospectively from hospital records.
Analysis was performed using appropriate statistical tests.
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